Teva Pharmaceutical Industries has finalized a $900 million agreement to acquire Emalex Biosciences, integrating a first-in-class therapy into its neuroscience pipeline. This acquisition follows Teva's robust Q1 2026 performance, reporting approximately $4 billion in revenue, significantly bolstered by innovative product sales. The deal is expected to close by Q3 2026 and reflects Teva's ongoing commitment to expand its portfolio in critical therapeutic areas, including CNS.
“Teva · to acquire · Emalex Biosciences · adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline”
“Teva · gains · biosimilar momentum · with U.S. FDA approval of PONLIMSI™ and Dual Filing Acceptance for Biosimilar Candidate to Xolair®”
“Teva Pharmaceutical Industries · has · Q1 revenue · $4 billion”
“Teva Pharmaceutical Industries · has · non-GAAP EPS · $0.53”
“Teva Pharmaceutical Industries · was founded in · 1901 · true”
“Teva Pharmaceutical Industries · has · market cap · 42.077B”
“Teva Pharmaceutical Industries · operates in · United States, Europe, Israel, and internationally · true”
“Teva Pharmaceutical Industries · has · total employees · 31,173”
“Teva Pharmaceutical Industries · focuses on · CNS, respiratory, and oncology areas · true”
“Teva Pharmaceutical Industries · offers · BENDEKA and TREANDA injections · for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma”
“Teva Pharmaceutical Industries · offers · COPAXONE · to treat patients with relapsing forms of multiple sclerosis”
“Teva Pharmaceutical Industries · offers · AJOVY · for the preventive treatment of migraine in adults”
